Small molecule · Inhibitor of ileal bile acid transporter (IBAT) (SLC10A2) · developed by Mirum
Maralixibat is a reversible inhibitor of the ileal bile acid transporter (IBAT) that decreases bile acid reabsorption from the terminal ileum.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Apr 10, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07290257 | Phase 4 | Alagille Syndrome | Recruiting | MIRM |
| NCT06553768 | Phase 3 | Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC) | Active not recruiting | MIRM |
| NCT02061540 | Phase 2 | Primary Sclerosing Cholangitis (PSC) | Completed | MIRM |
| NCT02057718 | Phase 2 | Progressive Familial Intrahepatic Cholestasis (PFIC) | Completed | MIRM |
| NCT06193928 | N/A | Alagille Syndrome | Recruiting | MIRM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Alagille SyndromeCholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)Progressive Familial Intrahepatic CholestasisPrimary Sclerosing Cholangitis (PSC)Progressive Familial Intrahepatic Cholestasis (PFIC)
Updated Oct 3, 2026. Something wrong or missing? Report it on the MIRM page.
See MIRM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MIRM catalysts and pipeline →